These comparative safety differences make AOD-9604 potentially suitable for individuals who might not tolerate full growth hormone therapy or who have contraindications to traditional GH use
This substitution may potentially increase the resistance of the peptide to enzymatic degradation and improve its stability
If these symptoms persist, consult with your healthcare provider
We proposed to continue to apply the reporting ratio, when applicable, to all HCPCS codes to which we have proposed status indicator assignments of J1, J2, P, Q1, Q2, Q3, R, S, T, V, and U (other than New Technology APCs to which we have proposed status indicator assignments of S and T)
This sensitive area may also appear slightly red